The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Hydrocortisone in Severe Community-Acquired Pneumonia
Abstract
BACKGROUND: Whether the antiinflammatory and immunomodulatory effects of glucocorticoids may decrease mortality among patients with severe community-acquired pneumonia is unclear. METHODS: In this phase 3, multicenter, double-blind, randomized, controlled trial, we assigned adults who had been admitted to the intensive care unit (ICU) for severe community-acquired pneumonia to receive intravenous hydrocortisone (200 mg daily for either 4 or 7 days as determined by clinical improvement, followed by tapering for a total of 8 or 14 days) or to receive placebo. All the patients received standard therapy, including antibiotics and supportive care. The primary outcome was death at 28 days. RESULTS: A total of 800 patients had undergone randomization when the trial was stopped after the second planned interim analysis. Data from 795 patients were analyzed. By day 28, death had occurred in 25 of 400 patients (6.2%; 95% confidence interval [CI], 3.9 to 8.6) in the hydrocortisone group and in 47 of 395 patients (11.9%; 95% CI, 8.7 to 15.1) in the placebo group (absolute difference, -5.6 percentage points; 95% CI, -9.6 to -1.7; P = 0.006). Among the patients who were not undergoing mechanical ventilation at baseline, endotracheal intubation was performed in 40 of 222 (18.0%) in the hydrocortisone group and in 65 of 220 (29.5%) in the placebo group (hazard ratio, 0.59; 95% CI, 0.40 to 0.86). Among the patients who were not receiving vasopressors at baseline, such therapy was initiated by day 28 in 55 of 359 (15.3%) of the hydrocortisone group and in 86 of 344 (25.0%) in the placebo group (hazard ratio, 0.59; 95% CI, 0.43 to 0.82). The frequencies of hospital-acquired infections and gastrointestinal bleeding were similar in the two groups; patients in the hydrocortisone group received higher daily doses of insulin during the first week of treatment. CONCLUSIONS: Among patients with severe community-acquired pneumonia being treated in the ICU, those who received hydrocortisone had a lower risk of death by day 28 than those who received placebo. (Funded by the French Ministry of Health; CAPE COD ClinicalTrials.gov number, NCT02517489.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Vincent, J. L., Moreno, R., Takala, J., Willatts, S., De Mendonça, A., Bruining, H., Reinhart, C. K., Suter, P. M., & Thijs, L. G. (1996) · Intensive Care Medicine · doi:10.1007/bf01709751 · Cited by 11,674
A Prediction Rule to Identify Low-Risk Patients with Community-Acquired Pneumonia
Fine, M. J., Auble, T. E., Yealy, D. M., Hanusa, B. H., Weissfeld, L. A., Singer, D. E., Coley, C. M., Marrie, T. J., & Kapoor, W. N. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701233360402 · Cited by 4,582
Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults
Jain, S., Self, W. H., Wunderink, R. G., Fakhran, S., Balk, R., Bramley, A. M., Reed, C., Grijalva, C. G., Anderson, E. J., Courtney, D. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500245 · Cited by 2,323
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Adjunctive glucocorticoid therapy in patients with septic shock.
Venkatesh, B., Finfer, S., Cohen, J., Rajbhandari, D., Arabi, Y., Bellomo, R., Billot, L., Correa, M., Glass, P., Harward, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705835 · Cited by 1,037
Hydrocortisone plus fludrocortisone for adults with septic shock.
Annane, D., Renault, A., Brun-Buisson, C., Megarbane, B., Quenot, J.-P., Siami, S., Cariou, A., Forceville, X., Schwebel, C., Martin, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705716 · Cited by 939
Self-citationHydrocortisone Infusion for Severe Community-acquired Pneumonia: A Preliminary Randomized Study
Confalonieri, M., Urbino, R., Potena, A., Piattella, M., Parigi, P., Puccio, G., Della Porta, R., Giorgio, C., Blasi, F., Umberger, R., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200406-808oc · Cited by 857
Musher, D. M., & Thorner, A. R. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1312885 · Cited by 626
Cited by
Qadir, N., Sahetya, S., Munshi, L., Summers, C., Abrams, D., Beitler, J., Bellani, G., Brower, R. G., Burry, L., Chen, J.-T., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202311-2011st · Cited by 444
Metadata
- Authors
- Dequin, P.-F., Meziani, F., Quenot, J.-P., Kamel, T., Ricard, J.-D., Badie, J., Reignier, J., Heming, N., Plantefève, G., Souweine, B., Voiriot, G., Colin, G., Frat, J.-P., Mira, J.-P., Barbarot, N., François, B., Louis, G., Gibot, S., Guitton, C., Giacardi, C., Hraiech, S., Vimeux, S., L’Her, E., Faure, H., Herbrecht, J.-E., Bouisse, C., Joret, A., Terzi, N., Gacouin, A., Quentin, C., Jourdain, M., Leclerc, M., Coffre, C., Bourgoin, H., Lengellé, C., Caille-Fénérol, C., Giraudeau, B., & Le Gouge, A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-05-25
- Volume
- 388
- Issue
- 21
- Pages
- 1931-1941
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4328048577
- Cited by
- 468
- References
- 28
- FWCI
- 78.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hydrocortisone in Severe Community-Acquired Pneumonia. https://app.cochat.ai/papers/10.1056/nejmoa2215145
- The paper
- Dequin, P.-F., Meziani, F., Quenot, J.-P., Kamel, T., Ricard, J.-D., Badie, J., Reignier, J., Heming, N., Plantefève, G., Souweine, B., Voiriot, G., Colin, G., Frat, J.-P., Mira, J.-P., Barbarot, N., François, B., Louis, G., Gibot, S., Guitton, C., . . . Le Gouge, A. (2023). Hydrocortisone in Severe Community-Acquired Pneumonia. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2215145
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.